A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...
The deal, which involves up to 8 “next-generation” weight loss medications and could be worth more than $18 billion, ranks as ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results